Asensus Surgical, Inc. announced that Kitakyushu General Hospital, a hospital in the Kyushu area of Japan, entered into an agreement to lease and utilize a second Senhance® Surgical System, at the end of December 2022.
First hospital to install a second Senhance Surgical System
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that Kitakyushu General Hospital (“Kitakyushu”), a hospital in the Kyushu area of Japan, entered into an agreement to lease and utilize a second Senhance® Surgical System, at the end of December 2022. Kitakyushu is the first hospital to install multiple Senhance Surgical Systems.
The hospital previously initiated their first Senhance system in January of 2020, and since has completed over 300 procedures utilizing Performance-Guided Surgery.
“We are very excited to see one of our first Japanese placements expanding their Senhance program to include a second system,” said Anthony Fernando, Asensus Surgical President and CEO. “This milestone speaks to the clinical value that the Senhance System and the Intelligent Surgical Unit™ bring to a surgeon, and hospital, as well as the wide applicability of the system to many different types of procedures in multiple specialities.”
Asensus Surgical’s technology platform, the Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments.
“Given the immense success of the first Senhance System, we are thrilled to be adding another unit to our surgical offerings,” said Dr. Naoki Nagata, President of Kitakyushu General Hospital. “We have received very positive feedback from our Senhance surgeons and patients in the last 3 years, and are pleased to be expanding the utilization of the Senhance Systems to deliver better and safer outcomes for our patients.”
About Kitakyushu General Hospital
Kitakyushu General Hospital is a prestigious institution and is recognized as one of the major hospitals in Kitakyushu. It offers both advanced and emergency medical care and is a core part of the Kitakyushu Hospital Group. It is a 360-bed facility that contains a critical care center and is the only general hospital in the Kitakyushu Hospital Group.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and Kitakyushu General Hospital initiating its second Senhance Surgical System. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the second Senhance Surgical System at Kitakyushu General Hospital speaks to the clinical value that the Senhance System and the ISU bring to a surgeon and hospital and whether expanding the utilization of Senhance Systems by Kitakyushu General Hospital will deliver better and safer outcomes for its patients. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Isabella Rodriguez, 708-833-1572
CG Life
irodriguez@cglife.com
